Different Views on Adolescent Abortion

PEDIATRICS ◽  
1993 ◽  
Vol 92 (4) ◽  
pp. 639-640
Author(s):  
PATRICIA LEE JUNE
Keyword(s):  
American Academy ◽  
Maternal Mortality ◽  
Disease Control ◽  
American Academy Of Pediatrics ◽  
Centers For Disease Control

The article, "Adolescent Abortion: Views of the Membership of the American Academy of Pediatrics" was interesting but contained some false implications. The authors imply that it is natural for pediatricians to support abortion because, in part, it is safer than childbirth. This implies that childbirth is dangerous for adolescents, but the facts show that maternal mortality is lower for adolescents than for any other age, and in fact, there were no reported deaths related to childbirth between 1980 and 1985 in the 19 states reporting to the Maternal Mortality Collaborative and the Centers for Disease Control for women younger than 15 years of age. The risk for all ages combined was less than 1 in 10 000, and less than that for adolescents. Is a 1 in 10 000 risk a rational reason to kill one of our patients?

Health Supervision Visits: Should the Immunization Schedule Drive the System?

PEDIATRICS ◽  
1987 ◽  
Vol 79 (4) ◽  
pp. 581-582
Author(s):  
ROBERT J. HAGGERTY
Keyword(s):  
American Academy ◽  
Disease Control ◽  
Immunization Schedule ◽  
Health Supervision ◽  
American Academy Of Pediatrics ◽  
Centers For Disease Control ◽  
Well Child Visit ◽  
Child Visit

The Centers for Disease Control (CDC) recently recommended that the vaccines usually given at the 15- and 18-month visits could be given simultaneously at 15 months, thereby omitting the 18-month well-child visit. There is little doubt that measles-mumps-rubella (MMR) immunization, now recommended by the American Academy of Pediatrics to be given at 15 months of age, and the diphtheria-tetanus-pertussis (DTP) and oral polio booster immunizations, now recommended to be given at 18 months of age, could be given together with no problem at 15 months. But this is not a good enough reason to abandon the 18-month well-child visit. Although I will not argue that we have solid evidence for the effectiveness of any well-child procedures other than immunizations, I believe that the 18-month visit is one of the more important ones and should not be discontinued for all children.

Tuberculin Testing in the Pediatric Office and Clinic

PEDIATRICS ◽  
1979 ◽  
Vol 64 (6) ◽  
pp. 965-966
Author(s):  
Edwin L. Kendig
Keyword(s):  
American Academy ◽  
Disease Control ◽  
School Children ◽  
Tuberculin Test ◽  
Pediatric Clinic ◽  
American Academy Of Pediatrics ◽  
Tuberculin Testing ◽  
The Difference ◽  
Low Rate

Another article in this issue of Pediatrics, "Assessment of Tuberculin Screening in an Urban Pediatric Clinic," (p 856) again focuses attention on a weighty question: Is routine use of the tuberculin test important? The authors have pointed out the difference in philosophy of the Center for Disease Control, and the American Academy of Pediatrics. The Center for Disease Control recommends that routine tuberculin testing for school children and other similar programs be abandoned if the yield of positive tuberculin reactions is less than 1%1; this recommendation is based on the assumption that discovery of cases at this low rate will not have epidemiologic impact (italics added).

Perinatal Group B Streptococcal Disease: A Summary of Revised Guidelines from the Centers for Disease Control

2003 ◽  
Vol 22 (1) ◽  
pp. 23-28
Author(s):  
Jeanette Zaichkin
Keyword(s):  
Disease Control ◽  
Group B Streptococcus ◽  
Morbidity And Mortality ◽  
Mortality Weekly Report ◽  
American Academy Of Pediatrics ◽  
Control And Prevention ◽  
Complete Report ◽  
Group B Streptococcal Disease ◽  
Centers For Disease Control ◽  
Group B

Recommendations for prevention of perinatal Group B Streptococcus (GBS) were issued in 1996 by the American College of Obstetricians and Gynecologists and the Centers for Disease Control and Prevention (CDC), followed in 1997 by the American Academy of Pediatrics (AAP). Although increased prevention activities during the 1990s resulted in a striking decline in incidence, GBS disease remains a leading infectious cause of morbidity and mortality among newborns in the U.S. Using available evidence and expert opinion, the CDC issued revised guidelines in August 2002 that replace the 1996 recommendations. This article, taken directly from the Morbidity and Mortality Weekly Report (August 16, 2002), presents a summary of the revised recommendations most applicable to neonatal nursing. The complete report is available at http://www.cdc.gov/mmwr/PDF/RR/RR5111.pdf.

Prophylaxis and Treatment of Neonatal Gonococcal Infections

PEDIATRICS ◽  
1980 ◽  
Vol 65 (5) ◽  
pp. 1047-1048
Author(s):  
Sydney Segal ◽  
Walter B. Anyan ◽  
Reba M. Hill ◽  
Ralph E. Kauffman ◽  
Howard Mofenson ◽  
...  
Keyword(s):  
American Academy ◽  
Disease Control ◽  
Silver Nitrate ◽  
Nitrate Solution ◽  
Newborn Infants ◽  
Silver Nitrate Solution ◽  
Gonococcal Infection ◽  
Ophthalmic Ointment ◽  
American Academy Of Pediatrics ◽  
Primary Agent

The Center for Disease Control (CDC), after consultation with a panel of experts, has revised its recommendations for prevention of gonococcal ophthalmia neonatorum. These recommendations now state, "ophthalmic ointment or drops containing tetracycline or erythromycin or a 1% silver nitrate solution" are effective and acceptable.1-3 This is a change from previous recommendations which highlighted silver nitrate as the primary agent for prophylaxis.4 The American Academy of Pediatrics' committees support these recommendations. The prevalence of largely asymptomatic genital gonococcal infection in pregnant women and the occurrence of gonococcal ophthalmia in untreated infants (estimated at 28%)5 born to infected women indicate the need for continued prophylaxis for all newborn infants.

DEPARTMENT OF CORRECTIONS

1993 ◽  
Vol 14 (4) ◽  
pp. 154-154
Keyword(s):  
American Academy ◽  
Disease Control ◽  
Medical Record ◽  
Meningococcal Disease ◽  
Index Case ◽  
Nasal Carriage ◽  
Index Patient ◽  
American Academy Of Pediatrics ◽  
Record Review ◽  
Middle Column

In the Addendum on page 18 of the January 1993 issue, the page reference should be 354, not 394. In the Medical Record Review on page 67 of the February 1993 issue, the reference to the sample form in the last paragraph of the middle column should have noted that the form was on page 69. Two abstracts regarding rifampin prophylaxis (September 1992, page 354 and October 1992, page 370) differ about whether the index patient should receive rifampin treatment. Dr. Shelov responds: It was stated in the October abstract that the index case of meningococcal disease should receive rifampin prophylaxis, but this is not the recommendation of the REDBOOK Committee of the American Academy of Pediatrics. Rather, this opinion is the consensus of other experts, including those from the Centers for Disease Control. Many children who have meningococcal disease now are treated with ceftriaxone. Because this antibiotic eradicates nasal carriage of the bacteria, rifampin use is not justified for the index case treated with ceftriaxone. I hope this clarifies further the directions for rifampin prophylaxis in meningococal disease.

Sign in / Sign up

Export Citation Format

Share Document